Results of a Phase 1 clinical trial (GH001-HV-103) to determine the safety and tolerability of mebufotenin (5-MeO-DMT), administered via inhalation (GH001) in healthy subjects
QPS and GH enrolled healthy volunteers for a Phase I trial to determine the safety and tolerability of a single administration or a single-day IDR of GH001.